CDEK
← All drugs Report issue

xylitol

Small moleculeexperimental

Xylitol is a chemical compound with the formula C5H12O5, or HO(CH2)(CHOH)3(CH2)OH; specifically, one particular stereoisomer with that structural formula. It is a colorless or white crystalline solid. It is classified as a polyalcohol and a sugar alcohol, specifically an alditol. Of the common sugar alcohols, only sorbitol is more soluble in water. — Wikipedia

Clinical trial activity

61 trials · 71 clinical orgs · 0 marketing orgs

Phase 1
8
Phase 2
20
Phase 3
13
Phase 4
3

Earliest trial started Jan 1, 2001 (NCT00066040)

Timeline

2000s

  1. Jan 1, 2003

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2009

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2012

    Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

OC[C@@H](O)[C@H](O)[C@@H](O)CO
Mol. weight
152.15 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • d-xylitol
  • d-xylitol
  • e967
  • e967
  • e967-xylitol
  • xylitol
  • xylitol
  • xylitol
  • xylitol
  • xylitol
  • xylitol
  • xylitol
  • xylitol

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07022678Phase 3Jan 20, 2026National Cancer Institute (NCI)
NCT06799039Early Phase 1 (Phase 1)Sep 1, 2025Harvard University
NCT06851611Phase 1Jan 21, 2025Rokote Laboratories Finland Oy
NCT05852587Phase 1May 1, 2024Harvard University
NCT06579339N/AMay 5, 2023Giresun University
NCT05579639Phase 2Nov 30, 2022National Institute of Dental and Craniofacial Research (NIDCR), University of Cincinnati
NCT05635929N/AOct 11, 2022Mucosa Innovations, S.L.
NCT05361122N/ASep 1, 2022University of Washington
NCT04854486Phase 3Dec 16, 2021Larkin Community Hospital
NCT04420780N/AAug 31, 2021University of Bern, University of Milan, University of Sassari, World Health Organization
NCT05463484Phase 2/Phase 3 (Phase 3)Jul 13, 2021Mucosa Innovations, S.L., University of Granada
NCT04731363N/AMar 10, 2021The Cleveland Clinic
NCT04585061N/ANov 1, 2020Riyadh Elm University
NCT04858620Phase 3Aug 30, 2020Larkin Community Hospital
NCT04610801Phase 3Aug 8, 2020Ferrer Medical Innovations, Larkin Community Hospital, Xlear
NCT03889015N/AJun 30, 2020Cairo University
NCT04086212Phase 2May 31, 2020D'Annunzio University of Chieti–Pescara, Iperboreal Pharma Srl
NCT04199897N/AMar 16, 2020University of Copenhagen
NCT04310514N/AMar 9, 2020Medical University of Gdansk
NCT06108921N/AFeb 1, 2020Taichung Veterans General Hospital
Showing 20 of 61 trials
Page 1 / 4

Organizations

Research & Development (71)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of BernAcademic/Hospital6612014
National Institute of Dental and Craniofacial Research (NIDCR)Government5032001
Harvard UniversityAcademic/Hospital3322010
Iperboreal Pharma SrlFor profit3322019
Larkin Community HospitalAcademic/Hospital3312020
University of IowaAcademic/Hospital3322009
University of TurkuAcademic/Hospital3132004
University of WashingtonAcademic/Hospital3222003
D'Annunzio University of Chieti–PescaraAcademic/Hospital2012019
GlaxoSmithKlineFor profit2122011
Mucosa Innovations, S.L.For profit2222021
St. Claraspital BaselAcademic/Hospital2012016
University of California, San FranciscoAcademic/Hospital2212007
University of CincinnatiAcademic/Hospital2212019
University of MilanAcademic/Hospital2012018
University of SassariAcademic/Hospital2112018
Augusta UniversityAcademic/Hospital1112011
Baylor UniversityAcademic/Hospital1112015
Cairo UniversityAcademic/Hospital1112020
Case Western Reserve UniversityAcademic/Hospital1112007
71 organizations
Page 1 / 4